MX358594B - Factores de riesgo de enfermedad y métodos de uso. - Google Patents

Factores de riesgo de enfermedad y métodos de uso.

Info

Publication number
MX358594B
MX358594B MX2013008068A MX2013008068A MX358594B MX 358594 B MX358594 B MX 358594B MX 2013008068 A MX2013008068 A MX 2013008068A MX 2013008068 A MX2013008068 A MX 2013008068A MX 358594 B MX358594 B MX 358594B
Authority
MX
Mexico
Prior art keywords
methods
risk factors
disease risk
active agent
disease
Prior art date
Application number
MX2013008068A
Other languages
English (en)
Other versions
MX2013008068A (es
Inventor
D Roses Allen
Original Assignee
Zinfandel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zinfandel Pharmaceuticals Inc filed Critical Zinfandel Pharmaceuticals Inc
Publication of MX2013008068A publication Critical patent/MX2013008068A/es
Publication of MX358594B publication Critical patent/MX358594B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método ex vivo para determinar el riesgo de desarrollo de la enfermedad de Alzherimer en un sujeto, que comprende: (a) detectar a partir de una muestra biológica que contiene ácido desoxirribnonuclico tomado de dicho sujeto, una variante genética del gen TOMM40 asociado con riesgo incrementado o disminuido de la enfermedad de Alzheimer, en donde dicha variante es rs10524523, y en donde dicha detección comprende determinar una longitud poli-T del mismo; (b) determinar si dicho sujeto está en riesgo incrementado o disminuido del desarrollo de la enfermedad de Alzherimer con base en dicha longitud poli-T, y (c) cuando se determina que dicho sujeto está en riesgo incrementado del desarrollo de la enfermedad de Alzheimer, el sujeto se identifica como un candidato para recibir tratamiento con pioglitazona.
MX2013008068A 2011-01-10 2011-02-17 Factores de riesgo de enfermedad y métodos de uso. MX358594B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431294P 2011-01-10 2011-01-10
PCT/US2011/025241 WO2012096680A1 (en) 2011-01-10 2011-02-17 Disease risk factors and methods of use

Publications (2)

Publication Number Publication Date
MX2013008068A MX2013008068A (es) 2014-01-20
MX358594B true MX358594B (es) 2018-08-27

Family

ID=46507376

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008068A MX358594B (es) 2011-01-10 2011-02-17 Factores de riesgo de enfermedad y métodos de uso.

Country Status (5)

Country Link
AU (1) AU2011354696B2 (es)
BR (1) BR112013017444A2 (es)
CA (1) CA2824024A1 (es)
MX (1) MX358594B (es)
WO (1) WO2012096680A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103898233A (zh) * 2014-04-18 2014-07-02 宁波大学 一种辅助诊断冠心病的检测试剂盒及其检测方法
GB201805554D0 (en) * 2018-04-04 2018-05-16 Wren Therapeutics Therapy for protein misfolding disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508959A (ja) * 2005-09-22 2009-03-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 認識機能の改善のためのロシグリタゾンおよびドネペジルの組合せ
EP2324126B1 (en) * 2008-08-12 2014-04-23 Zinfandel Pharmaceuticals, Inc. METHOD OF IDENTIFYING Alzheimer's DISEASE RISK FACTORS

Also Published As

Publication number Publication date
AU2011354696A1 (en) 2013-05-02
MX2013008068A (es) 2014-01-20
AU2011354696B2 (en) 2015-03-05
BR112013017444A2 (pt) 2016-09-27
CA2824024A1 (en) 2012-07-19
WO2012096680A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
NZ710443A (en) Method of identifying disease risk factors
UA114704C2 (uk) Способи та лікарські засоби для лікування хвороби альцгеймера
MX2013008793A (es) Clasificacion de ubicacion a base de anuncio para un sistema de red geo-social.
WO2011139345A3 (en) Pathway recognition algorithm using data integration on genomic models (paradigm)
EP2257644A4 (en) GENETIC MODIFICATIONS ASSOCIATED WITH AUTISM AND AUTISMIC PHENOTYPE AND METHODS OF USING THEM FOR THE DIAGNOSIS AND TREATMENT OF AUTISM
WO2013066764A3 (en) Alzheimer's disease signature markers and methods of use
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
EP3498729A3 (en) Therapeutic targets for alzheimer's disease
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
GB201122123D0 (en) Genetic analysis to determine ingredient efficacy
WO2012054681A3 (en) Methods for selecting medications for treating patients having attention-deficit hyperactivity disorder
EP2134863A4 (en) GENETIC MODIFICATIONS ON CHROMOSOME 16 AND METHODS OF USING THE SAME FOR THE DIAGNOSIS AND TREATMENT OF TYPE I DIABETES
IN2014MN01493A (es)
MX358594B (es) Factores de riesgo de enfermedad y métodos de uso.
SG195170A1 (en) Methods of treating or preventing rheumatic disease
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2011163607A3 (en) Olfactory receptor copy number association with age at onset of alzheimer's disease
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.
SA515360200B1 (ar) محاكيات عامل نمو خلية كبدية كعوامل علاجية
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
EP4289970A3 (en) Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis
BRPI0817771A2 (pt) Ésteres polienilciclopropanocarboxílicos com alta atividade inseticida.
TN2012000607A1 (en) Method for predicting a therapy response in subjects with multiple sclerosis
MX2013007817A (es) Metodo y sistema para la entrega automatizada de mensajes de soporte de equipo.

Legal Events

Date Code Title Description
FG Grant or registration